Sargent Investment Group LLC Has $1.51 Million Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Sargent Investment Group LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 34.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,295 shares of the company's stock after selling 51,000 shares during the period. Sargent Investment Group LLC's holdings in Teva Pharmaceutical Industries were worth $1,511,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $29,000. Golden State Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Compagnie Lombard Odier SCmA purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. Finally, Versant Capital Management Inc lifted its stake in shares of Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after buying an additional 4,312 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TEVA shares. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday, July 18th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Trading Up 1.4%

Shares of TEVA traded up $0.24 during mid-day trading on Wednesday, hitting $16.53. The company had a trading volume of 5,621,256 shares, compared to its average volume of 10,326,459. The business's 50-day simple moving average is $16.98 and its 200-day simple moving average is $16.87. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The stock has a market cap of $18.95 billion, a PE ratio of -14.36, a P/E/G ratio of 0.96 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The business's revenue was up 1.9% compared to the same quarter last year. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.